P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency 

Slides:



Advertisements
Similar presentations
Metastatic melanoma treatment: Combining old and new therapies Ryan J. Davey, Andre van der Westhuizen, Nikola A. Bowden Critical Reviews in Oncology /
Advertisements

Gastric cancer Critical Reviews in Oncology / Hematology
Umesh K. Narta, Shamsher S. Kanwar, Wamik Azmi 
Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.
Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: A systematic review  Cloé Brami, Ting Bao, Gary Deng  Critical.
Novel targets in gastric and esophageal cancer
Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Invasive lobular breast cancer and its variants: How special are they for systemic therapy decisions?  Séverine Guiu, Anita Wolfer, William Jacot, Pierre.
Organization of the clinical activity of Geriatric Oncology: Report of a SIOG (International Society of Geriatric Oncology) task force  Silvio Monfardini,
The case for wider use of recombinant factor VIII concentrates
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical.
Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: A systematic review of the literature  Omar Abdel-Rahman,
Amy M. Lin, Charles J. Ryan, Eric J. Small 
Genistein: Its role in metabolic diseases and cancer
Arne R. M. van der Bilt, Elisabeth G. E
Angiogenesis and hepatocellular carcinoma
Abhimanyu Ghose, Ria Kundu, Tahir Latif 
Critical Reviews in Oncology / Hematology
Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: From pathology to treatment  Judith Maresch, Sebastian F. Schoppmann,
Olfa Baroudi, Amel Benammar-elgaaied 
Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight  Giuseppe Aprile, Elena Ongaro, Marzia Del Re, Stefania.
Gwo Yaw Ho, Natasha Woodward, Jermaine I.G. Coward 
Critical Reviews in Oncology / Hematology
Molecular and serum markers in hepatocellular carcinoma: Predictive tools for prognosis and recurrence  Ashish Singhal, Muralidharan Jayaraman, Danny.
The Wnt signaling pathway in cancer
Immunotherapy, an evolving approach for the management of triple negative breast cancer: Converting non-responders to responders  Mai F. Tolba, Hany A.
Gerhard J. Molderings  Critical Reviews in Oncology / Hematology 
Inhibitor of MAP kinase activation blocks colon cancer growth
Connecting COX-2 and Wnt in cancer
Treatment of Glioma in the 21st Century: An Exciting Decade of Postsurgical Treatment Advances in the Molecular Era  Joon H. Uhm, MD, Alyx B. Porter,
Laetitia Seguin, Sara M. Weis, David A. Cheresh  Cell Stem Cell 
Chapter 12: The Cell Cycle
Dan Gordon  Gastroenterology  Volume 114, Issue 4, (April 1998)
Chapter 12: The Cell Cycle
Chapter 12: The Cell Cycle
Integrins and Mutant p53 on the Road to Metastasis
Integrins and Mutant p53 on the Road to Metastasis
Volume 29, Issue 3, Pages (March 2016)
Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer  Vassiliki Papadimitrakopoulou,
Volume 25, Issue 4, Pages (December 2018)
Volume 15, Issue 8, Pages R282-R283 (April 2005)
Uncovering a Tumor Suppressor for Triple-Negative Breast Cancers
EGFR T790M Mutation: A Double Role in Lung Cancer Cell Survival?
A. Craig Lockhart, Mace L. Rothenberg, Jordan D. Berlin 
Angiogenesis and hepatocellular carcinoma
Chemokines and leukocyte trafficking in rheumatoid arthritis
Signal Transduction: RABGEF1 Fingers RAS for Ubiquitination
AP Biology The Cell Cycle.
Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways as Therapeutic Targets for Colorectal Cancer  Thomas Winder, Heinz–Josef.
A New FOXO Pathway Required for Leukemogenesis
RAS and PD-L1: A Masters’ Liaison in Cancer Immune Evasion
Erratum Journal of Thoracic Oncology
LKB1 and Src: Antagonistic Regulators of Tumor Growth and Metastasis
SRC and STAT Pathways Journal of Thoracic Oncology
Powering Tumor Metastasis with Recycled Fuel
Tumor Metabolism: MAGE-A Proteins Help TRIM Turn Over AMPK
The Dual Role of Bone Morphogenetic Proteins in Cancer
EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer  Allison Ackerman, MD, Michael A. Goldstein,
Endocytic trafficking of CFTR in health and disease
Marco Terenzio, Giampietro Schiavo, Mike Fainzilber  Neuron 
Simon Ekman, MD, PhD, Murry W. Wynes, PhD, Fred R. Hirsch, MD, PhD 
Chapter 12: The Cell Cycle
Chapter 12: The Cell Cycle
All Roads Lead to the Ribosome
Co-opted integrin signaling in ErbB2-induced mammary tumor progression
A new key in breast cancer metastasis
Gankyrin: An intriguing name for a novel regulator of p53 and RB
Anthony N. Imbalzano, Stephen N. Jones  Cancer Cell 
Turning Reciprocal Feedback Regulation into Combination Therapy
Skp2, the FoxO1 hunter Cancer Cell
Presentation transcript:

P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency  Iuliana Shapira, Annette Lee, Reena Vora, Daniel R. Budman  Critical Reviews in Oncology / Hematology  Volume 88, Issue 2, Pages 284-292 (November 2013) DOI: 10.1016/j.critrevonc.2013.05.003 Copyright © 2013 Elsevier Ireland Ltd Terms and Conditions

Fig. 1 Endosomal trafficking of EGFR and integrin alpha5 beta1 in basal like breast cancer: A mutant form of the tumor suppressor protein p53 sequesters p63 (a transcription factor and p53 family member) and blocks its transcriptional activity. Sequestration of p63 by mutant p53 blocks its anti-metastatic abilities in part by diminishing the activity of Rab7 (the molecular motor responsible for the transport of EGFR cargo to the lysosome for degradation). This mechanism enhances the potency of EGFR signaling via recycling of EGFR and integrin back to the plasma membrane instead of allowing their degradation into the lysosome. An increase in EGFR and alpha5beta1 integrin signaling in the endosome and at the cell surface boosts the phosphorylation and activation of the Akt kinase and upregulates the invasive metastatic potential of these basal like breast cancer cells. Critical Reviews in Oncology / Hematology 2013 88, 284-292DOI: (10.1016/j.critrevonc.2013.05.003) Copyright © 2013 Elsevier Ireland Ltd Terms and Conditions

Fig. 2 The endosomal cycle: illustrated in blue arrows are epidermal growth factor receptors recycling pathways and in pink are secretory pathways. [95–97]. Critical Reviews in Oncology / Hematology 2013 88, 284-292DOI: (10.1016/j.critrevonc.2013.05.003) Copyright © 2013 Elsevier Ireland Ltd Terms and Conditions